• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

生物制剂与常规疗法：比较银屑病相关合并症的风险。

Biologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities.

出版信息

J Drugs Dermatol. 2023 Jun 1;22(6):621-622. doi: 10.36849/JDD.7119.

DOI:10.36849/JDD.7119
PMID:37276161
Abstract

Psoriasis is associated with multiple comorbidities. In this retrospective cohort analysis, we compared the comorbidities in patients who received biologic treatments with those who received conventional treatments. Our data indicates that biologics may be associated with lower rates of comorbidities in comparison to conventional therapy. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.7119.

摘要

银屑病与多种合并症相关。在这项回顾性队列分析中，我们比较了接受生物治疗和常规治疗的患者的合并症。我们的数据表明，与常规治疗相比，生物制剂可能与较低的合并症发生率相关。J 皮肤病药物治疗杂志。2023;22(5):doi:10.36849/JDD.7119.

相似文献

1
Biologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities.生物制剂与常规疗法：比较银屑病相关合并症的风险。
J Drugs Dermatol. 2023 Jun 1;22(6):621-622. doi: 10.36849/JDD.7119.
2
Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.英国皮肤科医师协会生物制剂干预登记处入组的银屑病患者的人口统计学和疾病特征。
Br J Dermatol. 2015 Aug;173(2):510-8. doi: 10.1111/bjd.13908. Epub 2015 Jul 6.
3
Serious infections among a large cohort of subjects with systemically treated psoriasis.一大群接受全身治疗的银屑病患者中的严重感染
J Am Acad Dermatol. 2017 Nov;77(5):838-844. doi: 10.1016/j.jaad.2017.07.047. Epub 2017 Sep 13.
4
Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study.芬兰银屑病患者的合并症和药物使用情况：一项基于人群的登记研究。
Acta Derm Venereol. 2023 Mar 9;103:adv00886. doi: 10.2340/actadv.v103.3491.
5
Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.银屑病患者不同治疗方案中的不良医疗状况：基于索赔数据的分析
J Drugs Dermatol. 2018 Nov 1;17(11):1211-1218.
6
A Retrospective Review of Patients' Response to Biologic Therapy for Psoriasis.回顾性分析生物制剂治疗银屑病的患者应答情况。
J Drugs Dermatol. 2021 Apr 1;20(4):442-449. doi: 10.36849/JDD.2021.5823.
7
Long-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics.生物制剂治疗应答不足的银屑病患者使用布罗达卢单抗的长期皮肤清除率。
J Drugs Dermatol. 2022 Apr 1;21(4):354-370. doi: 10.36849/JDD.6743.
8
Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.生物制剂治疗银屑病和银屑病关节炎的疗效和安全性及其对合并症的影响：文献综述。
Int J Mol Sci. 2020 Mar 1;21(5):1690. doi: 10.3390/ijms21051690.
9
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment.3 岁儿童伴甲营养不良的重度银屑病：生物治疗应答。
J Drugs Dermatol. 2022 Aug 1;21(8):897-899. doi: 10.36849/JDD.6888.
10
Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.生物疗法和传统全身疗法在中重度银屑病老年和成年患者中显示出相似的安全性和疗效。
J Drugs Dermatol. 2015 Aug;14(8):846-52.

引用本文的文献

1
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis).布罗达单抗治疗中度至重度银屑病的有效性：一项回顾性、真实世界多中心研究，重点关注肥胖和多次治疗失败患者-IL PSO（意大利银屑病概况）
J Clin Med. 2025 Feb 8;14(4):1087. doi: 10.3390/jcm14041087.
2
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study.生物疗法治疗重度斑块状银屑病的有效性和安全性：一项真实世界回顾性研究
J Pers Med. 2024 Feb 7;14(2):186. doi: 10.3390/jpm14020186.